Dr. Pr Emmanuel ANDRES received his MD degree in Internal Medicine in 1996, at the University of Strasbourg, France. He worked as an associated professor in the University Hospital of Strasbourg, France. In 1998 he worked as PhD in Molecular Biology in the Laboratory of Professor Hoffmann (2011, Nobel Prize of Medicine) in the field of cationic antimicrobial peptides and pathogens - host relations. In 2002, he was nominated Full Professor at the University of Strasbourg, France. He also was the head of an Internal Medicine Department (of 62 beads) in the University hospital of Strasbourg, France. He was awarded the French Society of Haematology, price for research in the field of anaemia related to cobalamin or folate deficiencies in 2004. Achievements include development of research in: all type of anaemia, neutropenia and thrombocytopenia, particularly drug-induced neutropenia and agranulocytosis or thrombocytopenia; haematopoietic growth factors; and cobalamin deficiencies. He also conducts several studies on inflammatory or immune disorders. His recent works also include research and development on human sounds analysis, electronic stethoscope, e-auscultation, and e-medicine. In that function he was recruited as advisor to several pharmaceutical and telemedicine companies and start-up companies. 

Oriented system diseases and hematology , neutropenia, agraulocytoses, thrombocytopenia, anemia deficiency, drug ... and autoimmune diseases (Coordinator competence center for immune thrombocytopenia and anemia) and continued his research on vitamin B12 deficiency. 

Dr. Claudio Fozza obtained his degree in Medicine at the University of Sassari in 2000 and his Specialization in Haematology in 2004 under the supervision of Prof M. Longinotti. In 2006 he started his academic teaching at the University of Sassari, chair of Haematology, and became consultant in Haematology. From January 2005 to December 2006 he attended the Hammersmith Campus at Imperial College in London, as Honorary Clinical Assistant and Clinical Trial Coordinator at the Dept. of Haematology chaired by Prof. J Apperley and as Clinical Research Fellow, Stem Cell Biology Section, Dept. of Immunology under the supervision of Prof F. Dazzi.

Dr. Abdulkareem Mohammed Al Momen Obtained his MB, BS,in 1976 from King Saud University, Riyadh.He got his Fellowship in 1986 from the Royal College of Physicians & Surgeons of Canada in Internal Medicine.He Obtained Canadian Board of Internal Medicine at University of Toronto (U of T), Canada, 1986. American Board of Internal Medicine 1986, and American Board of Hematology 1988.

Department of Pathology and Laboratory Medicine

Center of Excellence in Thrombosis & Hemostasis

 

Dr. Ken H. Young is professor of the University of Texas MD Anderson Cancer Center. He obtained his degree from Zhejiang University School of Medicine, Zhejiang, China, MD, 1984, Medicine University of Lund School of Medicine, Malmo, Sweden, PhD, 1995, Department of Pathology and Laboratory Medicine, and his Postgraduate Training: Research Fellowship, Cardiovascular Hematology Program, University of Oklahoma Health Science Center, Oklahoma City. Clinical Fellowship, University of Nebraska Medical Center, Omaha, NE

He received awards from Lund University School of Medicine, 1995 Graduate Student Research Scholar Award. Howard Hughes Medical Institute Fellowship Award in Cardiovascular-Hematology Program

University of Oklahoma Health Science Center, 1996.Myeloma SPORE 1st DRP Award

The University of Texas MD Anderson Cancer Center, 2011-2013. IRG Award, 2nd

The University of Texas MD Anderson Cancer Center, 2014-2015 Myeloma SPORE 2nd DRP Award

The University of Texas MD Anderson Cancer Center, 2014-2015. 

EBV+ Aggressive Lymphoma: Biology, Mechanism and Molecular Targets 

Dr. C. Cameron Yin has received her MD from Beijing Medical University and her PhD from the University of Wisconsin-Madison. She is currently an associate professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center and UT Graduate School of Biomedical Sciences. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, Hematology and Molecular Genetic Pathology. In addition to clinical responsibilities on the Leukemia, Lymphoma and Molecular Diagnostic Laboratory services, Dr. Yin has been actively participating in multiple research projects in leukemia and lymphoma, which has led to over 100 research papers and over 20 book chapters. She serves as members of editorial boards for over 20 journals and ad hoc reviewers for over 30 journals. Her major research interests include molecular genetic aberrations in leukemia and lymphoma, development of molecular methodologies for the diagnosis, prognosis and minimal residual disease monitoring of hematopoietic neoplasms, mechanisms of resistance to tyrosine kinase inhibitors in patients with chronic myelogenous leukemia, as well as the role of immunoglobulin gene rearrangement in acute myeloid leukemia.

Molecular genetic aberrations in leukemia and lymphoma

Development of molecular methodologies for the diagnosis, prognosis and minimal residual disease monitoring of hematopoietic neoplasms.

Mechanisms of imatinib resistance in patients with chronic myelogenous leukemia.

Immunoglobulin gene rearrangement in acute myeloid leukemia.

Dr. Menaa (PhD, MBA, MD candidate) is an internationally inter- and multi-disciplinary professional with holistic concept of Medicine. More than 10 years experiences in academic institutions (e.g. France, USA, Germany, Brazil) and industrial sectors (e.g. Guerbet SA, SANOFI, Fluorotronics Inc.). He is an independent consulting expert, researcher and Chief Editor of Journal of Nanomedicine and Nanotechnology He is also member of various scientific committees, boards and associations, and organized the “Target Meeting´s 1st World Nanomedicine and Nanobiotechnology Online ConferenceHe has contributed to over 100 scientific articles, 200 international events, and is the recipient of various recognitions. 

Oncology, Gerontology, Genetics, Biochemistry, Pharmacy and Nanomedicine.

Dr. Bradley S Fletcher received his MD/PhD degree from the University of California, Los Angeles in 1994. His PhD thesis involved the cloning and characterization of several transiently induced sequences, termed TIS genes which included TIS10 (COX2). He went on to Stanford University for internal medicine residency and a hematology fellowship. There he conducted research in the laboratory of Dr. Gary Nolan and worked on retroviral cDNA library cloning and the use of transposons for gene delivery. He joined the Department of Pharmacology and Therapeutics at the University of Florida in 1999, and rose to the rank of Associate Professor. His research effort has focused on the use of transposons as vehicles to facilitate long-term gene expression following non-viral gene delivery. This approach has been used to treat various conditions in animal models including hemophilia, pulmonary hypertension and acute graft rejection. Research funding has been obtained from the Veteran Administration, American Heart Association, National Hemophilia Foundation and Florida Biomedical Research Program. Dr. Fletcher’s clinical activities include attending the inpatient hematology consultation service at Shands Hospital and outpatient clinical hematology. Dr. Bradley S Fletcher received his MD/PhD degree from the University of California, Los Angeles in 1994. His PhD thesis involved the cloning and characterization of several transiently induced sequences, termed TIS genes which included TIS10 (COX2). He went on to Stanford University for internal medicine residency and a hematology fellowship. There he conducted research in the laboratory of Dr. Gary Nolan and worked on retroviral cDNA library cloning and the use of transposons for gene delivery. He joined the Department of Pharmacology and Therapeutics at the University of Florida in 1999, and rose to the rank of Associate Professor. His research effort has focused on the use of transposons as vehicles to facilitate long-term gene expression following non-viral gene delivery. This approach has been used to treat various conditions in animal models including hemophilia, pulmonary hypertension and acute graft rejection. Research funding has been obtained from the Veteran Administration, American Heart Association, National Hemophilia Foundation and Florida Biomedical Research Program. Dr. Fletcher’s clinical activities include attending the inpatient hematology consultation service at Shands Hospital and outpatient clinical hematology. 

Areas of clinical and research interests:

Gene delivery and gene therapy

Genetics of hematologic disorders

Benign and Malignant Hematology

Myeloproliferative Disorders

Myelodysplastic Syndrome

Atypical hematologic disorders

Dr.Andrea Piccin is a consultant haematologist currently working at the Haematology Department & Bone Marrow Transplantation Unit of San Maurizio Regional Hospital of Bolzano, South Tirol, Italy. He also actively collaborates with the Medical University of Innsbruck in Austria on development of future research projects in Haematology. Over the last years he has been working in the main Units of Haematology in Dublin Hospitals in Ireland. In 2009 Dr Piccin obtained a PhD degree at the University of Trinity College Dublin on a study on “New insight in Sickle Cell Anaemia pathophisiology”. Other activities comprise a study on “Autologus Recovery in Aplastic Anaemia” on behalf of the EBMT Severe Aplastic Anaemia working-party. Previous experience include a MD thesis on “Tandem PBSCT for Multiple Myeloma” (Verona University, Italy) and another MD degree in Paediatric Oncohaematology “Gene Therapy in Medulloblastoma in vivo and in vitro” (Padua University, Italy). He received his Medical Degree in 1996 at Padua University and the Higher Specialist Degree in Haematology in 2002 at Verona University.

Dr.Andrea Piccin is currently the principal investigator of two National projects on Lymphoma on behalf of the Fondazione Italiana Linfomi (FIL). His main areas of research have focused on evidence-based peer-reviewed haemato-oncology clinical trials and on key  clinical questions within the field of Sickle Cell Anaemia, Aplastic Anaemia of paediatric and adults and the elucidation of the relationship between the protein C activation pathway and systemic inflammatory response sepsis syndromes in children with meningitis.

Dr.Andrea Piccin is internationally recognised as an expert in the field of microparticles. His famous article “Circulating microparticles: pathophysiology and clinical implications.” has received over 450 citations todate.

He is author and coauthor of more than 200 research original articles, letters, books chapters and book translations.

Dr.Piccin has been also awarded by the Italian President Giorgio Napolitano for his contribution in the assistance of sick patients with the “Medal of Solidarity” and the honour of Sir“Cavaliere”. 

Haematology & Bone Marrow Transplantation 

Dr. Mendoza completed his medical school in the Catholic University (Ecuador) and his certification in medical oncology from Autonomous University of Barcelona (Spain). Dr Mendoza completed his residency in Medical Oncology at the Santa CreuiSant Pau Hospital in Barcelona, Spain. As a physician, he has an extensive record with the treatment of bad-prognosis cancer patients with high-dose chemotherapy and bone marrow transplantation. He continued with his PhD studies in the field of immunology-oncology at the Academy of Sciences in Prague where he worked in different types of anticancer vaccines and became an expert in the field of dendritic-cell based vaccines in experimental models.
 

Dr. Luis Mendoza has a position of Senior Medical Director within the Oncology Global Therapeutic Delivery Unit of QuintilesIMS. He has served as Medical and Scientific Advisor on many different clinical trials in the following indications: Breast Cancer, Ovarian Cancer, Cancer Related Anemia, Non-Small Cell Lung Cancer, Hodgkin Disease, Non-Hodgkin Lymphomas, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Prostate Cancer, Head and Neck Cancer, Colon-Rectal Cancer, Bladder Cancer, Advanced Solid Tumors and Advanced Hematologic Malignancies. He has great expertise in clinical pharmacology acquired after a record of more than 40 phase I clinical trials. He has overseen several oncology and non-oncology global drug development programs.
 

Prior to joining QuintilesIMS in January 2015, Dr. Luis Mendoza acquired 20+ years of hematology and oncology experience in the oncology medical practice combined with 13+ years of experience in clinical development of different oncology and general medical use compounds. Dr Mendoza has 9+ years in hem-oncology trials testing different anticancer compounds like targeted therapies, immunotherapies, oncolytic virus vaccines, antibody-drug conjugated vaccines, chemotherapies, PARP inhibitors and antiangiogenic drugs. Dr Mendoza continues with his altruistic unpaid labour as a consultant for physicians or cancer patients. He is author and co-author of several medical and scientific publications in peer review journals and author of educational manuals in cancer.

Oncology, immunotherapies, checkpoint inhibitors, early phase clinical development, dendritic cells.

Dr. Roomi earned a doctorate degree in Biochemical Toxicology from University of Surrey, England, and is a Fellow of American College of Nutrition (FACN). He is certified by the American Board of Toxicology (DABT) and American College of Nutrition (CNS). Dr. Roomi worked at the Linus Pauling Institute in Palo Alto, California for five years before joining the Dr. Rath research Institute as a Senior Research Scientist in 2000. His research interests include cancer, drug metabolism, environmental and occupational toxicology, organic synthesis, the molecular mechanism of toxicology and free radical and oxidative damage. Dr. Roomi has published over 200 papers in international journals, and has presented at over 200 national and international meetings, written chapters in book and author of several popular articles. He is a member of American Association of Cancer Research (AACR), the Federation of American Society of Experimental Biology (FASEB). The Society of Toxicology (SOT) and the American Society of Clinical Patholgy (ASCP).

Prof. Dr. Zhixiong Li studied human medicine at the Tongji Medical School in Wuhan in China between 1984 and 1990. He got his MD at the University of Hamburg in 1998. Prof. Li has long-term experiences in the development of retroviral vector systems for gene transfer into hematopoietic stem cells (HSCs), preclinical gene therapy trials, and leukemogenesis research. He reported for the first time leukemia development after gene therapy in a mouse model (Li Z et al., Science 2002). His group is currently interested in understanding how receptor protein tyrosine kinases (PTKs) contribute to leukemia development. Receptor PTKs are often deregulated in human cancers and may be important for self-renewal of cancer stem cells. Thus, receptors PTKs represent attractive targets for selective molecular therapy. Dr. Li´s lab has focused in part on the neurotrophin(NT) receptors and FLT3 signaling pathways. His group has obtained evidence for a previously underestimated role of NT signaling in leukemogenesis (Li Z et al., Science 2002; Li Z et al., Blood 2009; Yang M et al., Blood 2014). 

• Leukemogenesis of tyrosine kinases and targeted therapy
• Gene therapy
• Diagnosis of hematopoietic malignancies
• Stem Cell Biology